Buspirone and Depressive Symptoms
Buspirone does not typically cause sadness and crying as primary adverse effects, but paradoxically, it was less effective than bupropion at reducing depression severity when used as augmentation therapy in patients with major depressive disorder. 1
Evidence from FDA Labeling and Clinical Trials
The FDA-approved labeling for buspirone explicitly states that "mild depressive symptoms are common in GAD" and that buspirone has been shown to relieve anxiety in the presence of coexisting depressive symptoms 2. This indicates the drug is not contraindicated in depression and does not worsen it as a general rule.
Documented Adverse Effects
According to the FDA label, the most common adverse effects (≥1% incidence) include 2:
- CNS effects: Dizziness (12%), drowsiness (10%), nervousness (5%), lightheadedness (3%)
- Mood-related: Depression occurred in 2% of patients (same rate as placebo)
- Rare psychiatric effects: Dysphoria, depersonalization, and suicidal ideation were classified as "infrequent" (1/100 to 1/1,000 patients)
Depression occurred at the same 2% rate in both buspirone-treated and placebo-treated patients 2, suggesting buspirone does not increase the risk of depressive symptoms beyond baseline rates.
Clinical Trial Evidence
Efficacy in Depression with Anxiety
Multiple studies demonstrate buspirone's beneficial effects on depressive symptoms:
- In patients with GAD and coexisting mild depressive symptoms, buspirone reduced Hamilton Depression Rating Scale (HAM-D) scores by 5.7 points versus 3.5 points for placebo (p < 0.05) 3
- A 2025 multicenter study showed buspirone as adjunctive therapy significantly reduced both anxiety (HAMA) and depression (HAMD) scores in depressed patients already on antidepressants 4
- In elderly patients with anxiety secondary to neurotic depression, buspirone produced significantly greater improvement than placebo 5
Comparative Effectiveness Caveat
The key finding from American College of Physicians guidelines: When used as augmentation therapy for treatment-resistant depression, buspirone was less effective at reducing depression severity compared to bupropion augmentation, though both showed similar rates of response and remission 1. Additionally, discontinuation due to adverse events was lower with bupropion than with buspirone (moderate-quality evidence) 1.
Clinical Interpretation
Why Patients Might Report Sadness
If a patient reports sadness or crying on buspirone, consider:
- Inadequate treatment response: Buspirone may not be sufficiently treating underlying anxiety/depression, allowing symptoms to persist or worsen
- Underlying depression: The patient may have unrecognized or undertreated major depressive disorder
- Rare idiosyncratic reaction: While uncommon, dysphoria is listed as an infrequent adverse effect 2
- Nocebo effect: Depression occurs at equal rates with placebo 2
Common Pitfall to Avoid
Do not assume buspirone is causing depression simply because a patient develops sadness while taking it. The evidence shows buspirone typically improves depressive symptoms when they coexist with anxiety 2, 3. Instead, reassess whether:
- The underlying condition is adequately treated
- The diagnosis is correct (GAD vs. MDD)
- Another medication or life stressor is contributing
When to Switch Therapy
Based on guideline evidence, if buspirone augmentation is not adequately reducing depressive symptoms after 4-6 weeks, consider switching to bupropion augmentation, which showed superior efficacy for depression severity reduction 1.